CClinicalTrials.gg
CompletedNCT00705809Updated Jul 2, 2017

T-Cell Project: Epidemiologic Component

An observational study in Peripheral T-Cell Lymphoma, sponsored by National Cancer Institute (NCI). Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-02.

Sponsored by National Cancer Institute (NCI) · Observational

Study type
Observational
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Study summary

Background:

  • The T-Cell Project, sponsored by the International T-cell non-Hodgkin Lymphoma Study Group, is a consortium of institutions interested in achieving more detailed information on clinical and biological characteristics of T-cell lymphomas.
  • The T-Cell Project serves as a repository for data on patients with peripheral T-cell lymphoma (PTCL) worldwide. Its overall goal is to improve T-cell subtype classifications and evaluate treatment strategies for each subtype.

Objectives:

-To implement a standardized epidemiologic questionnaire into the ongoing T-Cell Project to allow evaluation of various potential risk factors for PTLCs.

Eligibility:

-Untreated patients 18 years of age and older who were diagnosed with PTLC September 1, 2006, or later.

Design:

-Patients complete a questionnaire containing the following information:

Demographic information

Smoking history and alcohol use

Personal history or cancer

History of cancer among first-degree relatives

Medical history

History of transplants

History of blood transfusions

Medication use

Occupational and residential history

Pesticide treatment

-The information collected is linked to clinical and pathologic information in the T-Cell Project database.

Read the detailed description

Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different morphological patterns, phenotypes, and clinical presentations. Although a number of case-control studies on non-Hodgkin lymphoma (NHL) have identified various risk factors for disease, including autoimmune conditions, family history of hematopoietic malignancies, smoking, hepatitis C infection, and host susceptibility, these risk factors largely pertain to B-cell lymphoma subtypes as they comprise well over 90 percent of all NHLs. At present, there are no known epidemiologic risk factors for PTCL or its subtypes. This is largely due to the lack of sample size of PTCL in any one epidemiologic study. The aim of this proposal is to implement a standardized epidemiologic risk factor questionnaire into the on-going T-Cell Project. Briefly, the T-Cell Project is an international consortium of on-going clinical trials on peripheral PTCL. It serves as a prospective collection of patients (greater than 18 years) worldwide with PTCL who are enrolled at participating medical institutions for treatment in a clinical trial. The overall goal of the T-Cell Project is to improve current T-cell subtype classifications and to evaluate different treatment strategies for each T-cell subtype. The specific goal of our proposal is to implement, within the T-Cell Project, a 20-minute standardized epidemiologic questionnaire to allow evaluation of various potential risk factors for T-cell lymphomas. Importantly, there are currently no known epidemiologic risk factors for PTCL. We plan to administer questionnaires to 800 PTCL patients; if successful this collection would be the largest database of PTCLs to date with epidemiologic data. If the questionnaire implementation of assessing epidemiological risk factors for PTCL among patients in the T-Cell Project is found logistically feasible, then descriptive and analytic epidemiologic analyses of the collected data to understand the etiology of PTCL would be pursued at the NCI in collaboration with members of the T-Cell Project. For such analyses, NCI would receive only fully anonymized and de-linked data with no identifiers.

02

Conditions studied

  • Peripheral T-Cell Lymphoma

Keywords

  • Epidemiology
  • Peripheral T-Cell Lymphoma
03

In context

Lymphoma, T-Cell

718 studies on the registry are indexed under Lymphoma, T-Cell; 120 are open to participants now.

This study's planned enrollment of 800 is above the median of 174 across 57 observational studies indexed under Lymphoma, T-Cell.

Browse Lymphoma, T-Cell studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,506 studies on the registry; 334 are open to participants now.

Of its 402 completed or terminated interventional studies of FDA-regulated products, 365 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age greater than or equal to 18 years
  • Histologically confirmed Periperal T-cell lymphoma on or after September 1, 2006

Exclusion criteria

EXCLUSION CRITERIA:

  • Age less than 18 years
  • Cases without histological confirmation
  • Cases diagnosed prior to September 1, 2006
05

Study design

Time perspective
Prospective
Enrollment
800 participants (estimated)
06

Study locations

1 site
  • National Cancer Institute (NCI), 9000 Rockville Pike
    Bethesda, Maryland 20892, United States
07

References and documents

Publications

  • Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med. 2000 Jul 13;343(2):108-17. doi: 10.1056/NEJM200007133430207. No abstract available. PubMed 10891520 ↗
  • Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med. 2000 Jul 6;343(1):37-49. doi: 10.1056/NEJM200007063430107. No abstract available. PubMed 10882768 ↗
  • Jones D, O'Hara C, Kraus MD, Perez-Atayde AR, Shahsafaei A, Wu L, Dorfman DM. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000 Jul 15;96(2):685-90. PubMed 10887135 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00705809
Lead sponsor
National Cancer Institute (NCI)
First posted
Jun 26, 2008
Start date
Jun 18, 2008
Completion
Jul 20, 2011
Last update
Jul 2, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion